Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Phase II Study of BNC210 in Adults With Post-Traumatic Stress Disorder (PTSD).

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase II Study of BNC210 in Adults With Post-Traumatic Stress Disorder (PTSD).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BNC 210 (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Therapeutic Use
  • Acronyms RESTORE
  • Sponsors Bionomics

    • Most Recent Events

    • 30 Jul 2024 According to a Bionomics media release, company announced that it will provide a corporate update and discuss the outcomes of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration regarding the advancement of BNC210 for the treatment of post-traumatic stress disorder (PTSD) into Phase 3.
    • 10 May 2021 According to a Bionomics media release, the dose of BNC-210 for Phase 2b PTSD trial has been selected based on data from this trial.
    • 03 Oct 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top